Search

Your search keyword '"Anwer, Faiz"' showing total 121 results

Search Constraints

Start Over You searched for: Author "Anwer, Faiz" Remove constraint Author: "Anwer, Faiz" Database Complementary Index Remove constraint Database: Complementary Index
121 results on '"Anwer, Faiz"'

Search Results

1. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.

2. Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma.

3. Disparities in time to treatment with oral antimyeloma medications.

4. Yield of repeat blood cultures in acute myeloid leukemia patients with febrile neutropenia and bacteremia following allogeneic hematopoietic stem cell transplant.

5. Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.

6. Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.

7. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.

8. Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy.

9. Role of Patient Characteristics and Insurance Type in Newly Diagnosed Multiple Myeloma Care Disparities.

10. Role of Palliative Care in the Supportive Management of AL Amyloidosis—A Review.

11. Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa‐1 trial eligibility criteria: A real‐world multicentre study.

12. Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management.

15. Validation of the GATMO score in predicting non‐relapse mortality following hematopoietic cell transplant in multiple myeloma patients.

16. Analysis of risk factors and prognostic factors of brain metastasis in gastric cancer: a surveillance, epidemiology and end-results database study.

17. Intravenous immunoglobulin prophylaxis is associated with decreased rate of infection‐related hospitalizations in multiple myeloma patients.

18. Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review.

19. Clinical Research in Chronic Lymphocytic Leukemia in Pakistan; A Systematic Review.

24. Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management.

25. Validation of the role of corrected DLCO in predicting outcomes post autologous hematopoietic cell transplant for multiple myeloma.

26. The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review.

27. Liquid biopsies and minimal residual disease in myeloid malignancies.

28. Diagnostic and Treatment Strategies for AL Amyloidosis in an Era of Therapeutic Innovation.

29. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs.

30. Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice.

33. Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management.

34. COVID-19 vaccine immune response in patients with plasma cell dyscrasia: a systematic review.

35. Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review.

36. Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high‐risk cytogenetics: A meta‐analysis of randomized controlled trials.

37. Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma.

39. Risk of Venous Thromboembolism in Multiple Myeloma Patients During the Immediate Peri-Autologous Hematopoietic Cell Transplantation Phase.

45. Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review.

46. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.

47. Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.

48. Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.

49. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study.

Catalog

Books, media, physical & digital resources